• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全球和区域范围内的多重用药现状及相关因素,1997-2022 年:伞式综述。

Global and regional prevalence of polypharmacy and related factors, 1997-2022: An umbrella review.

机构信息

Department of Family Medicine, Kyung Hee University Medical Center, Kyung Hee University College of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, South Korea.

Center for Digital Health, Medical Science Research Institute, Kyung Hee University College of Medicine, Seoul, South Korea; Department of Regulatory Science, Kyung Hee University, Seoul, South Korea.

出版信息

Arch Gerontol Geriatr. 2024 Sep;124:105465. doi: 10.1016/j.archger.2024.105465. Epub 2024 Apr 27.

DOI:10.1016/j.archger.2024.105465
PMID:38733922
Abstract

OBJECTIVE

Limited comprehensive evidence exists on the global prevalence of polypharmacy. This knowledge gap contributes to increased healthcare system costs and related public health concerns. Thus, we aimed to synthesize the current evidence on polypharmacy prevalence and associated factors in the general and older populations using an umbrella review.

METHODS

Our primary outcomes were global prevalence and related indicators of polypharmacy. We systematically searched Google Scholar, PubMed/MEDLINE, Embase, and CINAHL for studies published between the inception of each database until April 30, 2023.

RESULTS

Eleven meta-analyses incorporating 295 studies and 59,552,762 participants from 41 countries across six continents were identified. The global prevalence of polypharmacy in the general population is 37 %, with higher rates in older individuals (45 %), outpatients (48 %), and inpatients (52 %). North America showed a higher prevalence (52 %) than Asia (36 %) and Europe (36 %). Among frail elderly individuals, the prevalence of polypharmacy is 59 %, with the highest rates in Europe (68 %) and hospital settings (71 %).

CONCLUSION

The global prevalence of polypharmacy and its associated factors in older adults present a complex, multifaceted, and conflicting picture. Understanding the prevalence of polypharmacy and its associated factors may help reduce the number of multidrug prescriptions.

摘要

目的

关于全球范围内多重用药的流行率,目前仅有有限的综合证据。这一知识空白导致医疗保健系统成本增加,并引发相关公共卫生问题。因此,我们旨在通过伞式综述综合当前关于一般人群和老年人群中多重用药流行率及其相关因素的证据。

方法

我们的主要结局指标是全球多重用药的流行率和相关指标。我们系统地在 Google Scholar、PubMed/MEDLINE、Embase 和 CINAHL 上搜索了自每个数据库建立以来至 2023 年 4 月 30 日发表的研究。

结果

确定了 11 项荟萃分析,其中纳入了来自六大洲 41 个国家的 295 项研究和 59,552,762 名参与者。一般人群中多重用药的全球流行率为 37%,老年人(45%)、门诊患者(48%)和住院患者(52%)的比率更高。北美地区的流行率(52%)高于亚洲(36%)和欧洲(36%)。在体弱老年人中,多重用药的流行率为 59%,欧洲(68%)和医院环境(71%)的比率最高。

结论

老年人中多重用药的全球流行率及其相关因素呈现出复杂、多方面和相互矛盾的情况。了解多重用药的流行率及其相关因素可能有助于减少多药处方的数量。

相似文献

1
Global and regional prevalence of polypharmacy and related factors, 1997-2022: An umbrella review.全球和区域范围内的多重用药现状及相关因素,1997-2022 年:伞式综述。
Arch Gerontol Geriatr. 2024 Sep;124:105465. doi: 10.1016/j.archger.2024.105465. Epub 2024 Apr 27.
2
Prevalence of Polypharmacy in Elderly Population Worldwide: A Systematic Review and Meta-Analysis.全球老年人群中多药疗法的流行情况:系统评价和荟萃分析。
Pharmacoepidemiol Drug Saf. 2024 Aug;33(8):e5880. doi: 10.1002/pds.5880.
3
Prevalence of Polypharmacy and Risks of Potentially Inappropriate Medication Use in the Older Population in a Developing Country: A Systematic Review and Meta-Analysis.发展中国家老年人群多重用药的患病率及潜在不适当用药风险:一项系统评价与荟萃分析
Gerontology. 2022;68(2):136-145. doi: 10.1159/000516075. Epub 2021 May 11.
4
Prevalence and health outcomes of polypharmacy and hyperpolypharmacy in older adults with frailty: A systematic review and meta-analysis.衰弱老年人多重用药和超多重用药的患病率及健康结局:一项系统评价和荟萃分析
Ageing Res Rev. 2023 Jan;83:101811. doi: 10.1016/j.arr.2022.101811. Epub 2022 Nov 29.
5
Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis.抗精神病药联合用药的流行率、相关性、耐受性相关结局和疗效相关结局:系统评价和荟萃分析。
Lancet Psychiatry. 2024 Dec;11(12):975-989. doi: 10.1016/S2215-0366(24)00314-6. Epub 2024 Nov 12.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
Prevalence of Potentially Inappropriate Medications in Older Adults with Cognitive Impairment or Dementia Attending Memory Clinics: A Systematic Review and Meta-Analysis.认知障碍或痴呆老年患者在记忆门诊中潜在不适当药物的流行率:系统评价和荟萃分析。
J Alzheimers Dis. 2024;101(4):1107-1120. doi: 10.3233/JAD-240575.
8
Global Incidence and Prevalence of Chronic Rhinosinusitis: A Systematic Review.慢性鼻窦炎的全球发病率和患病率:一项系统评价
Clin Exp Allergy. 2025 Jan;55(1):52-66. doi: 10.1111/cea.14592. Epub 2024 Nov 7.
9
Prevalence of Polypharmacy, Hyperpolypharmacy and Potentially Inappropriate Medication Use in Older Adults in India: A Systematic Review and Meta-Analysis.印度老年人多重用药、超多重用药及潜在不适当用药的患病率:一项系统评价与荟萃分析
Front Pharmacol. 2021 May 19;12:685518. doi: 10.3389/fphar.2021.685518. eCollection 2021.
10
Polypharmacy in multimorbid older adults: protocol for a systematic review.多病共存的老年人中的多重用药:一项系统评价方案
Syst Rev. 2017 May 19;6(1):104. doi: 10.1186/s13643-017-0492-9.

引用本文的文献

1
Effects of photobiomodulation on multiple health outcomes: an umbrella review of randomized clinical trials.光生物调节对多种健康结局的影响:随机临床试验的系统综述
Syst Rev. 2025 Aug 6;14(1):160. doi: 10.1186/s13643-025-02902-3.
2
Health risk and disease burden of daily hospitalizations for vaginitis due to air pollution: evidence from a heavily-polluted-city in China.空气污染导致的阴道炎每日住院的健康风险和疾病负担:来自中国一个重度污染城市的证据。
BMC Public Health. 2025 Jul 29;25(1):2568. doi: 10.1186/s12889-025-23797-8.
3
Education about deprescribing for pre-licensed and licensed healthcare professionals: A scoping review.
针对未取得执照和已取得执照的医疗保健专业人员的减药教育:一项范围综述。
Br J Clin Pharmacol. 2025 Jun;91(6):1649-1659. doi: 10.1111/bcp.70040.
4
Development and Validation of Polypharmacy-Related Psychological Distress Scale (PPDS): A Preliminary Study.多重用药相关心理困扰量表(PPDS)的编制与验证:一项初步研究
Behav Sci (Basel). 2025 May 21;15(5):707. doi: 10.3390/bs15050707.
5
Prevalence of potentially inappropriate prescribing in community-dwelling older adults: an application of STOPP/START version 3 to The Irish Longitudinal Study on Ageing (TILDA).社区居住老年人潜在不适当处方的患病率:STOPP/START第3版在爱尔兰老龄化纵向研究(TILDA)中的应用
Eur Geriatr Med. 2025 Apr 28. doi: 10.1007/s41999-025-01201-3.
6
Implementation of an electronic medication management support system in hospitalised polypharmacy patients: study protocol of a stepped-wedge cluster-randomised controlled trial (TOP study).住院多重用药患者电子药物管理支持系统的实施:一项阶梯式楔形整群随机对照试验(TOP研究)的研究方案
BMJ Open. 2025 Apr 15;15(4):e084696. doi: 10.1136/bmjopen-2024-084696.
7
Frailty, multimorbidity, and polypharmacy: Proposal of the new concept of the geriatric triangle.衰弱、多病共存与多重用药:老年三角新概念提案
Geriatr Gerontol Int. 2025 May;25(5):657-662. doi: 10.1111/ggi.70046. Epub 2025 Apr 14.
8
Polypharmacy and Potentially Inappropriate Medication in Iranian People With Metabolic Syndrome: Epidemiological Aspects and Related Factors, a Multi-Level Cross-Sectional National Study.伊朗代谢综合征患者的多重用药和潜在不适当用药:流行病学特征及相关因素,一项全国性多层次横断面研究
Health Sci Rep. 2025 Apr 9;8(4):e70600. doi: 10.1002/hsr2.70600. eCollection 2025 Apr.
9
Education about deprescribing for pre-licensed and licensed healthcare professionals: A scoping review.针对未获得执照和已获得执照的医疗保健专业人员的减药教育:一项范围综述。
Br J Clin Pharmacol. 2025 Jun;91(6):1649-1659. doi: 10.1002/bcp.70040. Epub 2025 Mar 24.
10
Exploring Australian pharmacists' experiences with the electronic National Residential Medication Chart: a qualitative descriptive study.探索澳大利亚药剂师使用电子全国住院药物图表的经历:一项质性描述性研究。
Int J Clin Pharm. 2025 Mar 14. doi: 10.1007/s11096-025-01894-3.